Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1992-01-30
1993-07-13
Lacey, David L.
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
53038815, 435 7021, 4351722, 43524027, C12N 512, C12P 2108
Patent
active
052274713
ABSTRACT:
Monoclonal antibodies that bind specifically to prostate carcinoma and do not bind substantially to normal prostate or benign prostatic hyperplasia, as well as hybridoma cell lines producing the monoclonal antibodies are disclosed. In one embodiment, a monoclonal antibody designated MAb PD41 is disclosed. A new antigen designated prostate mucin antigen is disclosed in isolated, substantially pure form. In addition, methods for using the hybridoma cell lines, the monoclonal antibody and/or the antigen for diagnosis, prophylaxis and/or treatment of prostate carcinoma are disclosed.
REFERENCES:
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4741900 (1988-05-01), Alverez et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 5055404 (1991-10-01), Ueda et al.
Beckett, et al Cancer Research 51:1326-1333 1991.
Mazur, et al Am J. Clinical Pathology 93:466-470, 1990.
Wright et al., Prostate tumor-specific mucin-like antigen differentiates ign prostate hyperplasia from well-differentiated prostate adenocarcinoma, J. Urol., 145:259A, Abstract, 329, 1991.
Wright et al., Monoclonal antibody PD-41 identifies a marker specifically expressed on prostate carcinomas, J. Urol. 139:174A, Abstract 45, 1988.
Wright et al., TURP-27 and PD41; New markers for prostate cancer Proc. Amer. Assoc. Cancer Res. 29:249, Abst. 992. 1988.
Chu et al., Biochem Markers for Cancer, pp. 117-136, 1982.
Taga et al., Prostate 4:141-150, 1983.
Wang et al., Invest. Urol. 17:159-163, 1979.
Starling et al., Cancer Res. 46:367-374, 1986.
Horoszewicz et al., Anticancer Res. 7:929-936, 1987.
Kim et al., Cancer Res. 48:4543-4548, 1988.
Bazinet et al., Cancer Res. 48:6938-6942, 1988.
Wright et al., Radiopharm. 3:89, Abst. 193, 1990.
Frankel et al., Proc. Nat'l Acad. Sci. (USA) 79:903-907, 1982.
Raynor et al., J. Nat'l. Cancer Inst. 73:617-625, 1981.
Carroll et al. Clin. Immunol. Immunopath. 33:268-281, 1984.
Ware et al., Cancer Res. 42:1215-1222, 1982.
Kuroki et al., Int. J. Cancer 44:208-218, 1989.
Feller et al., Immunol. Series 53:631-672, 1990.
Mullinak et al., Proc. Nat'l. Acad. Sci. (USA) 87:8095-8099, 1990.
Starling et al., Cancer Res. 42:3084-3089, 1982.
Brothman et al., Int. J. Cancer 44:898-903, 1989.
Hoehn et al., Prostate 1:95-104, 1980.
Hoehn et al., Prostate 5:445-452, 1984.
Wright et al., Cancer Res. 43:5509-5516, 1983.
Wahab et al., Int. J. Cancer 36:677-683, 1985.
Kjeldsen et al., Cancer Res. 48:2214-2220, 1988.
Hakomori et al., Ann Rev. Immunol. 2:103-126 (1984).
Sell, Hum Pathol. 21(10):1003-1019, 1990.
Seregni et al., J. Nucl. Med. All. Sci. 34:314-320 (1990).
Lillehoj et al., Mol. Immunol. 19:1199-1202, 1982.
Nadji et al., Ann. NY Acad. Sci. 390:133-141, 1982.
Naritoku et al., J. Histochem. Cytochem. 30:253-260, 1982.
Papsidero et al., Hybridoma 2:139-147, 1983.
Frankel et al., Cancer Res. 42:3714-3718, 1982.
Wright et al., Int. J. Cancer 46:39-49, 1990.
Webb et al., Cancer Immunol. Immunother. 14:155-166, 1983.
Carroll et al., Surv. Synth. Path. Res. 3:189-200, 1984.
Raynor et al., Prostate 9:21-31, 1986.
Lingren et al., Cancer Immun. Immunother. 22:1-7, 1986.
Starling et al., Cancer Res. 45:804-808, 1985.
Kim et al., Cancer Res. 49:2379-2382, 1989.
Webb et al., Cancer Immunol. Immunother. 17:7-17, 1984.
Lopes et al., Cancer. Res. 50:6423-6429, 1990.
Arai et al., J. Immunol. 138:3259-3263, 1987.
Lipford et al., Cancer Res. 51:2296-2301, 1991.
Wright et al., Int. J. Cancer 47:717-725, 1991.
Wright et al., The Prostate 17:301-316, 1990.
Bazinet et al., J. Urol. 141:(Abs. 133), 1989.
Gallee et al., The Prostate 9:33-45, 1986.
Adams Donald E.
Eastern Virginia Medical School of the Medical College of Hampto
Lacey David L.
LandOfFree
Monoclonal antibody PD41 that binds to a prostate mucin antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody PD41 that binds to a prostate mucin antigen , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody PD41 that binds to a prostate mucin antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2313031